Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Ranbaxy Laboratories, Ltd., Paonta Sahib, India
WARNING LETTER
•Ranbaxy Laboratories, Ltd., Paonta Sahib, India•March 7, 2008

Ranbaxy Laboratories, Ltd., Paonta Sahib, India – FDA Warning Letter, Mar 7, 2008

Record Details

An FDA inspection of Ranbaxy Laboratories Limited's Batamandi (Unit II) facility in Paonta Sahib, India, from March 3-7, 2008, revealed significant deviations from U.S. Current Good Manufacturing Practice (CGMP) Regulations (21 CFR Parts 210 and 211). These deficiencies render the drug products adulterated under Section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act. The FDA considers Batamandi (Unit II) part of the existing Paonta Sahib facility, indicating systemic CGMP issues, including a failure of production and quality management, following a previous Warning Letter in 2006 regarding stability testing. Key violations included inaccurate equipment cleaning records where verifying personnel were not present (21 CFR 211.182), incomplete batch production and control records due to absent supervising/checking personnel (21 CFR 211.188(b)(11)), and an SOP allowing manufacturing without an authorized master production record (21 CFR 211.188(a)). Additionally, the Quality Control Unit's review procedures for production records were inadequate, and investigations into discrepancies were not extended to other batches (21 CFR 211.192). The FDA requires a response within 30 days, emphasizing that continued non-compliance will lead to disapproval of new applications and refusal of admission for products, with the exception of Ganciclovir oral capsules due to its sole-source status, subject to third-party verification.

Company
Ranbaxy Laboratories, Ltd., Paonta Sahib, India
Inspection date
March 7, 2008
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Richard L. Friedman (Director)
View Company Profile

ID · 1925b173-a4d6-43c2-8de5-e401a0d76d00

Violation Codes9
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 211FD&C Act 501(a)(2)(B)FD&C Act 801(a)(3)21 U.S.C. 381(a)(3)21 CFR 211.18221 CFR 211.188(b)(11)21 CFR 211.192

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Ranbaxy Laboratories, Ltd., Paonta Sahib, India
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.